Modeling excess zeroes in an integrated analysis of vaccine safety
In prophylactic vaccine studies in healthy populations, many subjects do not experience a single adverse event (AE). Thus, the number of AEs observed in such clinical trials may be difficult to model because of an excess of zeroes relative to the parametric distributions assumed. To determine which...
Saved in:
Published in | Human vaccines & immunotherapeutics Vol. 14; no. 6; pp. 1530 - 1533 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Taylor & Francis
03.06.2018
Taylor & Francis Group |
Subjects | |
Online Access | Get full text |
ISSN | 2164-5515 2164-554X 2164-554X |
DOI | 10.1080/21645515.2018.1433972 |
Cover
Loading…
Abstract | In prophylactic vaccine studies in healthy populations, many subjects do not experience a single adverse event (AE). Thus, the number of AEs observed in such clinical trials may be difficult to model because of an excess of zeroes relative to the parametric distributions assumed. To determine which type of modeling provides a better fit for observed AE data, a variety of models were applied to data from an integrated safety database from clinical trials of the meningococcal vaccine MenB-FHbp (Trumenba®, bivalent rLP2086; Pfizer Inc, Philadelphia, PA). MenB-FHbp was the first vaccine approved in the United States to prevent meningococcal serogroup B disease in individuals aged 10 to 25 years. Specifically, this report presents an integrated analysis of AEs from 8 randomized controlled trials that compared MenB-FHbp to placebo or active controls. The number of AEs occurring from dose one to 30 days after the last dose was analyzed. Six models were compared: standard Poisson and negative binomial models and their corresponding zero-inflation and hurdle models. Models were evaluated for their ability to predict the number of AEs and by goodness-of-fit statistics. Models based on the Poisson distribution were a poor fit. The zero-inflated negative binomial model and negative binomial hurdle model provided the closest fit. These results suggest that zero-inflated or hurdle models may provide a better fit to AE data from healthy populations compared with conventional parametric models. |
---|---|
AbstractList | In prophylactic vaccine studies in healthy populations, many subjects do not experience a single adverse event (AE). Thus, the number of AEs observed in such clinical trials may be difficult to model because of an excess of zeroes relative to the parametric distributions assumed. To determine which type of modeling provides a better fit for observed AE data, a variety of models were applied to data from an integrated safety database from clinical trials of the meningococcal vaccine MenB-FHbp (Trumenba®, bivalent rLP2086; Pfizer Inc, Philadelphia, PA). MenB-FHbp was the first vaccine approved in the United States to prevent meningococcal serogroup B disease in individuals aged 10 to 25 years. Specifically, this report presents an integrated analysis of AEs from 8 randomized controlled trials that compared MenB-FHbp to placebo or active controls. The number of AEs occurring from dose one to 30 days after the last dose was analyzed. Six models were compared: standard Poisson and negative binomial models and their corresponding zero-inflation and hurdle models. Models were evaluated for their ability to predict the number of AEs and by goodness-of-fit statistics. Models based on the Poisson distribution were a poor fit. The zero-inflated negative binomial model and negative binomial hurdle model provided the closest fit. These results suggest that zero-inflated or hurdle models may provide a better fit to AE data from healthy populations compared with conventional parametric models. In prophylactic vaccine studies in healthy populations, many subjects do not experience a single adverse event (AE). Thus, the number of AEs observed in such clinical trials may be difficult to model because of an excess of zeroes relative to the parametric distributions assumed. To determine which type of modeling provides a better fit for observed AE data, a variety of models were applied to data from an integrated safety database from clinical trials of the meningococcal vaccine MenB-FHbp (Trumenba®, bivalent rLP2086; Pfizer Inc, Philadelphia, PA). MenB-FHbp was the first vaccine approved in the United States to prevent meningococcal serogroup B disease in individuals aged 10 to 25 years. Specifically, this report presents an integrated analysis of AEs from 8 randomized controlled trials that compared MenB-FHbp to placebo or active controls. The number of AEs occurring from dose one to 30 days after the last dose was analyzed. Six models were compared: standard Poisson and negative binomial models and their corresponding zero-inflation and hurdle models. Models were evaluated for their ability to predict the number of AEs and by goodness-of-fit statistics. Models based on the Poisson distribution were a poor fit. The zero-inflated negative binomial model and negative binomial hurdle model provided the closest fit. These results suggest that zero-inflated or hurdle models may provide a better fit to AE data from healthy populations compared with conventional parametric models.In prophylactic vaccine studies in healthy populations, many subjects do not experience a single adverse event (AE). Thus, the number of AEs observed in such clinical trials may be difficult to model because of an excess of zeroes relative to the parametric distributions assumed. To determine which type of modeling provides a better fit for observed AE data, a variety of models were applied to data from an integrated safety database from clinical trials of the meningococcal vaccine MenB-FHbp (Trumenba®, bivalent rLP2086; Pfizer Inc, Philadelphia, PA). MenB-FHbp was the first vaccine approved in the United States to prevent meningococcal serogroup B disease in individuals aged 10 to 25 years. Specifically, this report presents an integrated analysis of AEs from 8 randomized controlled trials that compared MenB-FHbp to placebo or active controls. The number of AEs occurring from dose one to 30 days after the last dose was analyzed. Six models were compared: standard Poisson and negative binomial models and their corresponding zero-inflation and hurdle models. Models were evaluated for their ability to predict the number of AEs and by goodness-of-fit statistics. Models based on the Poisson distribution were a poor fit. The zero-inflated negative binomial model and negative binomial hurdle model provided the closest fit. These results suggest that zero-inflated or hurdle models may provide a better fit to AE data from healthy populations compared with conventional parametric models. |
Author | Beeslaar, Johannes Absalon, Judith Perez, John Radley, David Patterson, Scott Maansson, Roger Jiang, Qin |
Author_xml | – sequence: 1 givenname: Roger surname: Maansson fullname: Maansson, Roger organization: Pfizer Vaccine Clinical Research and Development, Collegeville, PA, USA – sequence: 2 givenname: David surname: Radley fullname: Radley, David organization: Pfizer Vaccine Research and Development, Pearl River, NY, USA – sequence: 3 givenname: Qin surname: Jiang fullname: Jiang, Qin organization: Pfizer Innovative Health, Collegeville, PA, USA – sequence: 4 givenname: Johannes surname: Beeslaar fullname: Beeslaar, Johannes organization: Pfizer Vaccine Clinical Research and Development, Hurley, UK – sequence: 5 givenname: Scott surname: Patterson fullname: Patterson, Scott organization: Statistical Innovation, Sanofi Pasteur, Swiftwater, PA, USA – sequence: 6 givenname: Judith surname: Absalon fullname: Absalon, Judith organization: Pfizer Vaccine Research and Development, Pearl River, NY, USA – sequence: 7 givenname: John surname: Perez fullname: Perez, John organization: Pfizer Vaccine Clinical Research and Development, Collegeville, PA, USA |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29393713$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkU1vEzEQhi1UREvoTwDtkUuCvf5aCwmJVnxUKuICEjdr1jsbXG3sYjsV4dfjJWlEueCDPR4_887I71NyEmJAQp4zumK0o69apoSUTK5ayroVE5wb3T4iZ3N-KaX4dnKMmTwl5znf0Lo0bYVST8hpa7jhmvEzcvEpDjj5sG7wp8Ocm1-YIubGhwZC3QuuExQc6g2mXfa5iWNzB875gE2GEcvuGXk8wpTx_HAuyNf3775cflxef_5wdfn2eumE1mVpTIe9xo7LlnVC8UGOkrEWuOMOpQTsFdMdgGGmNxT7tlNc9DODHFSlFuRqrztEuLG3yW8g7WwEb_8kYlpbSMW7Ca0DNQoKzHRGi0Gg0UZx1G5oNZNczlpv9lq3236Dg8NQEkwPRB--BP_druOdVZRrUadfkJcHgRR_bDEXu_HZ4TRBwLjNlpn6xaaaJSr64u9exyb3JlRA7gGXYs4JxyPCqJ39tvd-29lve_C71r3-p875AsXHeWQ__af6N0IirjA |
CitedBy_id | crossref_primary_10_1002_sim_9575 |
Cites_doi | 10.1080/10543400600719384 10.2307/1912557 |
ContentType | Journal Article |
Copyright | 2018 Pfizer, Inc. 2018 Pfizer, Inc. |
Copyright_xml | – notice: 2018 Pfizer, Inc. 2018 Pfizer, Inc. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
DOI | 10.1080/21645515.2018.1433972 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
DocumentTitleAlternate | R. MAANSSON ET AL |
EISSN | 2164-554X |
EndPage | 1533 |
ExternalDocumentID | oai_doaj_org_article_ca6f40a198974d4e97963e7cd271535c PMC6037446 29393713 10_1080_21645515_2018_1433972 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: ; |
GroupedDBID | --- 00X 0YH 30N 4.4 53G AALUX AAYXX ABEIZ ABUPF ACGFS ADBBV ADCVX AECIN AENEX AGYJP AIJEM ALMA_UNASSIGNED_HOLDINGS ALQZU AOIJS ARJSQ BABNJ BAWUL BLEHA BOHLJ CCCUG CITATION DGEBU DIK EBS EJD H13 HYE IPNFZ KYCEM M4Z O9- RIG RPM TDBHL TFL TFW TTHFI CGR CUY CVF ECM EIF NPM 7X8 5PM GROUPED_DOAJ |
ID | FETCH-LOGICAL-c477t-998eb7e835218463d5f5112a3c3ce55aeb6178aa919b90eb28634bf511e3a63c3 |
IEDL.DBID | DOA |
ISSN | 2164-5515 2164-554X |
IngestDate | Wed Aug 27 01:30:36 EDT 2025 Thu Aug 21 18:33:01 EDT 2025 Fri Jul 11 10:33:03 EDT 2025 Thu Apr 03 07:08:39 EDT 2025 Thu Apr 24 22:57:11 EDT 2025 Tue Jul 01 02:46:05 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Keywords | hurdle models Poisson excess zeroes zero-inflated models negative binomial vaccine adverse events |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c477t-998eb7e835218463d5f5112a3c3ce55aeb6178aa919b90eb28634bf511e3a63c3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Area of expertise: statistical modelling, mathematical modelling. |
OpenAccessLink | https://doaj.org/article/ca6f40a198974d4e97963e7cd271535c |
PMID | 29393713 |
PQID | 1993991084 |
PQPubID | 23479 |
PageCount | 4 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_ca6f40a198974d4e97963e7cd271535c pubmedcentral_primary_oai_pubmedcentral_nih_gov_6037446 proquest_miscellaneous_1993991084 pubmed_primary_29393713 crossref_primary_10_1080_21645515_2018_1433972 crossref_citationtrail_10_1080_21645515_2018_1433972 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2018-06-03 |
PublicationDateYYYYMMDD | 2018-06-03 |
PublicationDate_xml | – month: 06 year: 2018 text: 2018-06-03 day: 03 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Human vaccines & immunotherapeutics |
PublicationTitleAlternate | Hum Vaccin Immunother |
PublicationYear | 2018 |
Publisher | Taylor & Francis Taylor & Francis Group |
Publisher_xml | – name: Taylor & Francis – name: Taylor & Francis Group |
References | cit0001 Akaike H (cit0012) 1973 TRUMENBA (meningococcal group B vaccine) (cit0002) 2014 cit0015 |
References_xml | – start-page: 267 volume-title: In: year: 1973 ident: cit0012 – volume-title: Full Prescribing Information year: 2014 ident: cit0002 – ident: cit0001 doi: 10.1080/10543400600719384 – ident: cit0015 doi: 10.2307/1912557 |
SSID | ssj0000702466 |
Score | 2.1132727 |
Snippet | In prophylactic vaccine studies in healthy populations, many subjects do not experience a single adverse event (AE). Thus, the number of AEs observed in such... |
SourceID | doaj pubmedcentral proquest pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 1530 |
SubjectTerms | Adolescent Adult Biostatistics - methods Child Drug-Related Side Effects and Adverse Reactions - epidemiology excess zeroes Female Humans hurdle models Male Meningococcal Vaccines - administration & dosage Meningococcal Vaccines - adverse effects negative binomial poisson Randomized Controlled Trials as Topic Short Report vaccine adverse events Young Adult zero-inflated models |
Title | Modeling excess zeroes in an integrated analysis of vaccine safety |
URI | https://www.ncbi.nlm.nih.gov/pubmed/29393713 https://www.proquest.com/docview/1993991084 https://pubmed.ncbi.nlm.nih.gov/PMC6037446 https://doaj.org/article/ca6f40a198974d4e97963e7cd271535c |
Volume | 14 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS8QwEB5UELyIb-uLCF6r3SZNtkcVRTx4UvBWknSCgnTF3RX11zuTdpddEbx4bDqhYWaa-YZMvgE4KU3GYdymJlc6VZi51KF2qbc9a4o8-NrHaos7ffOgbh-Lx5lWX1wT1tIDt4o781YHlVku7TGqVlgachk0vs4N_ayF592XYt5MMhX3YEOxJx5U5pQPpAQLisn1nX52xmM8xJVdfdorJAXlfC4wRf7-30Dnz9rJmWB0vQarHYoU5-3q12EBmw1YbvtKfm7CBXc443vmAj_4GoD4wrcBDsVzI2wjpgwRNT21lCRiEMS79XzILoY24OhzCx6ur-4vb9KuWULqlTGjlNImdAYZUFHSpmVdhGgE6aXHorDo-DKgtWWvdGVG-XRfS-VYBqXVJLUNS82gwV0QlEHQPJIl-KdcWVtfhtoW6FUIWdB5Amqiqcp3TOLc0OKl6nWEoxMFV6zgqlNwAqfTaa8tlcZfEy7YDFNhZsKOA-QfVecf1V_-kcDxxIgV_Tl8HGIbHIyHFZcuEjrO-iqBndao008RCGKiQJmAmTP33Frm3zTPT5GdWzOjj9J7_7H4fVhhhcTSNHkAS6O3MR4SCBq5I1iU2d1R9PpvLdr-oA |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Modeling+excess+zeroes+in+an+integrated+analysis+of+vaccine+safety&rft.jtitle=Human+vaccines+%26+immunotherapeutics&rft.au=Roger+Maansson&rft.au=David+Radley&rft.au=Qin+Jiang&rft.au=Johannes+Beeslaar&rft.date=2018-06-03&rft.pub=Taylor+%26+Francis+Group&rft.issn=2164-5515&rft.eissn=2164-554X&rft.volume=14&rft.issue=6&rft.spage=1530&rft.epage=1533&rft_id=info:doi/10.1080%2F21645515.2018.1433972&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_ca6f40a198974d4e97963e7cd271535c |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2164-5515&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2164-5515&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2164-5515&client=summon |